Long-acting (basal) insulin on every 2026 Puerto Rico Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 3 stand-alone Part D plans in Puerto Rico cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
| Drug | HealthSpring Extra Rx$50.00/moS5617-385 | HealthSpring Assurance Rx$65.70/moS5617-348 | AARP Medicare Rx Preferred from UHC$145.10/moS5820-037 |
|---|---|---|---|
| Lantusinsulin glargine | Tier 317% | Tier 322% | Tier 325% |
| insulin glargineunbranded Lantus | Not covered | Not covered | Tier 325% |
| Basaglarinsulin glargine | Not covered | Not covered | Not covered |
| Semgleeinsulin glargine-yfgn | Not covered | Not covered | Not covered |
| Rezvoglarinsulin glargine-aglr | Not covered | Not covered | Not covered |
| Toujeoinsulin glargine, U-300 | Tier 317% | Tier 322% | Tier 325% |
| Tresibainsulin degludec | Not covered | Not covered | Not covered |
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.